• Publications
  • Influence
Botulinum toxin.
The National Institutes of Health Consensus Development Conference on Clinical Use of Botulinum Toxin brought together neurologists, ophthalmologists, otolaryngologists, speech pathologists, andExpand
  • 270
  • 19
Recommendations for the use of botulinum toxin type A in the management of cerebral palsy.
Botulinum toxin type A (BTX-A) is increasingly being used for the treatment of childhood spasticity, particularly cerebral palsy. However, until very recently, all such use in this indication hasExpand
  • 383
  • 17
The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy.
An interdisciplinary European group of clinical experts in the field of movement disorders and experienced Botulinum toxin users has updated the consensus for the use of Botulinum toxin in theExpand
  • 192
  • 11
  • PDF
Botulinum toxin assessment, intervention and after‐care for lower limb spasticity in children with cerebral palsy: international consensus statement
Botulinum neurotoxin type‐A (BoNT‐A) has been used in association with other interventions in the management of spasticity in children with cerebral palsy (CP) for almost two decades. This consensusExpand
  • 131
  • 11
  • PDF
Feasibility of robotic‐assisted locomotor training in children with central gait impairment
Intensive, task‐specific training enabled by a driven gait orthosis (DGO) may be a cost‐effective means of improving walking performance in children. A paediatric DGO has recently been developed.Expand
  • 110
  • 9
Altered Neurochemistry in Former Professional Soccer Players without a History of Concussion.
Soccer is played by more than 250 million people worldwide. Repeatedly heading the ball may place soccer players at high risk for repetitive subconcussive head impacts (RSHI). This study evaluatesExpand
  • 87
  • 8
Safety and efficacy of botulinum toxin type A following long‐term use
Botulinum toxin serotype A (BoNT‐A) has long heritage of use leading to confidence in its safety and efficacy. The application of BoNT‐A does not lead to persistent histological changes in the nerveExpand
  • 141
  • 7
European consensus table 2006 on botulinum toxin for children with cerebral palsy.
An interdisciplinary group of experienced botulinum toxin users and experts in the field of movement disorders was assembled, to develop a consensus on best practice for the treatment of cerebralExpand
  • 113
  • 7
  • PDF
Robotic-assisted treadmill therapy improves walking and standing performance in children and adolescents with cerebral palsy.
OBJECTIVE Task-specific body-weight-supported treadmill therapy improves walking performance in children with central gait impairment. The aim of the study was to investigate the effect ofExpand
  • 119
  • 7
Medium‐term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1‐year follow‐up using gross motor function measure
One of the main goals when treating spasticity is to relieve pain and improve function. Intramuscular injection of botulinum toxin type A (BTX‐A) has gained widespread acceptance in the treatment ofExpand
  • 54
  • 7